# Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

> **NCT04017221** · — · COMPLETED · sponsor: **Canadian Network for Observational Drug Effect Studies, CNODES** · enrollment: 1249636 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Urosepsis
- Diabetic Ketoacidosis
- Lower Extremity Amputation

## Interventions

- **DRUG:** Sodium-glucose cotransporter 2 (SGLT2) inhibitors
- **DRUG:** Dipeptidyl peptidase-4 (DPP-4) inhibitors
- **DRUG:** Other treatment combinations

## Key facts

- **NCT ID:** NCT04017221
- **Lead sponsor:** Canadian Network for Observational Drug Effect Studies, CNODES
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 1249636 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017221, "Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04017221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*